ESC Congress 2020
News from ORION: Low interpatient variability in LDL-lowering response to inclisiran
Almost all high- and very high-risk patients achieved at least 30% reduction in LDL cholesterol levels with inclisiran adjunctive to maximally tolerated statin therapy, according to this latest analysis from the ORION trial programme, reported at ESC Congress 2020. Inclisiran is a novel siRNA therapeutic…
read more »
Evolocumab in AMI patients undergoing coronary intervention
Early treatment with the PCSK9 inhibitor evolocumab, on top of statin, may provide a feasible therapeutic approach for patients with an acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI), according to this Japanese study. Patients are at highest risk of recurrent events in the…
read more »
DA-VINCI: Need to do better with LDL cholesterol management in practice in Europe
Only one-third of patients in routine practice attain the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guideline-recommended LDL cholesterol goals, based on the results of the DA-VINCI study. These findings show that implementation of guideline-recommended management will require a practice change, especially among very…
read more »
HAUSER-RCT targets children/adolescents with heterozygous familial hypercholesterolaemia
Results from the HAUSER-RCT trial show that treatment with evolocumab safely reduced LDL cholesterol by almost 40% against a background of statin and diet, in children and adolescents with heterozygous familial hypercholesterolaemia. Heterozygous familial hypercholesterolaemia (FH) is one of the most common metabolic disorders, affecting…
read more »
HAUSER RCT: Expert viewpoint
HAUSER RCT showed that treatment with the PCSK9 monoclonal antibody evolocumab, against a background of usual care (statin, with ezetimibe in 12-15% of patients), was effective and safe in children and adolescents with heterozygous familial hypercholesterolaemia (FH, inherited high cholesterol) (1). The question is: Does…
read more »
HAUSER-RCT with evolocumab: what role in children with FH?
PCSK9 Forum Editor Professor Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) comments on the findings of the HASUER-RCT study and potential implications for patient care. HAUSER-RCT is an important study for the care of children and adolescents with familial hypercholesterolaemia (FH). The study…
read more »
